Showing results (11-20 of 48) with videos related to
Sort By:
Pageof 5
Chemical Biology & Drug Design|April 25, 2006
The discovery of tropane-derived CCR5 receptor antagonistsDuncan R Armour, Marcel J de Groot, David A Price, et al.Journal of Virology|April 30, 2010
A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41Edward J Murray, Daniel P Leaman, Nishant Pawa, et al.Journal of Virology|April 28, 2006
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoirMike Westby, Marilyn Lewis, Jeannette Whitcomb, et al.Antiviral Research|January 24, 2007
An inhibitor of the epidermal growth factor receptor function does not affect the ability of human papillomavirus 11 to form warts in the xenografted immunodeficient mouse modelTanya Parkinson, Mary K Howett, Patricia A Welsh, et al.Bioorganic & Medicinal Chemistry Letters|September 1, 2009
Pyrazole NNRTIs 3: optimisation of physicochemical propertiesCharles E Mowbray, Romuald Corbau, Michael Hawes, et al.Journal of Biomolecular Screening|September 29, 2004
Development and automation of a 384-well cell fusion assay to identify inhibitors of CCR5/CD4-mediated HIV virus entryJoe Bradley, Jasween Gill, Francois Bertelli, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|July 28, 2011
Disease-modifying therapeutic concepts for HIV in the era of highly active antiretroviral therapyScott L Butler, Hernan Valdez, Michael Westby, et al.Chemmedchem|October 16, 2008
Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitorsLyn H Jones, Gill Allan, Romuald Corbau, et al.Antimicrobial Agents and Chemotherapy|July 28, 2010
Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1Romuald Corbau, Julie Mori, Chris Phillips, et al.Bioorganic & Medicinal Chemistry Letters|September 15, 2009
Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidateCharles E Mowbray, Catherine Burt, Romuald Corbau, et al.Pageof 5